In this work we describe an immunotherapy approach using PPRHs directed against PD-1 and PD-L1 in PMA-differentiated THP-1 cells and PC3 cancer cells, respectively, to favor the elimination of tumor cells by macrophages. This evidence concerns the gene PDCD1 and neoplasm.